BUZZ-Biomea Fusion rises as diabetes drug shows promise
Shares of drug developer Biomea Fusionrise 3.4% to $1.23 premarketCo says experimental drug, icovamenib, helped patients with severe type 2 diabetes maintain better blood sugar control nine months after treatmentStudy presented at World Congress on Insulin Resistance in Los Angeles, co saysBMEA says drug aims to restore insulin-producing cells; tested in adults who failed up to three standard therapies No serious side effects reported; further trials planned with GLP-1 users later this year, says co As of last close, stock down ~69% YTD
Shares of drug developer Biomea Fusion (BMEA.O) rise 3.4% to $1.23 premarket
Co says experimental drug, icovamenib, helped patients with severe type 2 diabetes maintain better blood sugar control nine months after treatment
Study presented at World Congress on Insulin Resistance in Los Angeles, co says
BMEA says drug aims to restore insulin-producing cells; tested in adults who failed up to three standard therapies No serious side effects reported; further trials planned with GLP-1 users later this year, says co As of last close, stock down ~69% YTD
